2023-10-13 09:14:26 ET
- Biotech Tiziana Life Sciences ( NASDAQ: TLSA ) Friday announced that five out of six patients in the FDA-authorized Expanded Access Program showed a qualitative reduction in microglia activation.
- The reductions, as seen in six-month Positron Emission Tomography ( PET ) scans, were observed in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).
- Foralumab, TLSA's lead candidate, would now advance into phase 2 human clinical trials using a fully human intranasal anti-CD3 monoclonal antibody, the company added.
- Phase 2 trial screening for na-SPMS is set to begin in November 2023.
- Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) that binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets.
- TLSA +5.42% premarket to $0.7799
- Source: Press Release
For further details see:
Tiziana announces positive six-month PET scan results with its intranasal Foralumab